Lv22
200 积分 2025-07-30 加入
Acute lymphoblastic leukaemia
17天前
已完结
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
23天前
已完结
Re: Chimeric Antigen Receptor T Cells as Adjuvant Therapy for Unresectable Adenocarcinoma
23天前
已完结
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
3个月前
已完结
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
3个月前
已完结
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
3个月前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
3个月前
已完结
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
3个月前
已完结
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
3个月前
已完结
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
3个月前
已完结
皖公网安备34019202002308
